VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Darapladib shows promise in diabetic macular oedema

Placebo-controlled trial findings show that lipoprotein-associated phospholipase A2 inhibition modestly benefits the vision of patients with centre-involved diabetic macular oedema and warrants further investigation.

8 Jul 2015

Phase IIIb CONSIGN study confirms benefit of regorafenib in patients with pre-treated mCRC

The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers announced at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.

3 Jul 2015

Polypoidal choroidal vasculopathy shows distinct classification

Researchers have found that idiopathic polypoidal choroidal vasculopathy has significant clinical differences to neovascular age-related macular degeneration and suggest that it should be considered a distinct entity.

30 Jun 2015

ORT incidence increases in nAMD despite anti-VEGF treatment

Swiss researchers report that patients with neovascular age-related macular degeneration (nAMD) experience increased incidence of outer retinal tubulation over time, despite treatment with a vascular endothelial growth factor blocker.

30 Jun 2015

No overall survival benefit for bevacizumab in ovarian cancer

Addition of bevacizumab to first-line platinum-based chemotherapy does not improve overall survival in women with ovarian cancer, according to the mature data of the ICON7 trial.

26 Jun 2015

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO).

26 Jun 2015

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

New study reports more practical approach to heal the heart after a heart attack

Stem cell have been the main focus of healing therapy research because they can morph into new cells, and using a patient's own stem cells will not induce an autoimmune response. For healing after a heart attack, the ideal time to administer these therapies is when reopening the clogged blood vessel because the heart is easily accessible. While stem cells show promise for heart attack treatment, the process of harvesting and reintroducing the cells—which can take days or weeks—is too slow for this window.

17 Jun 2015

RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office on its novel, self-delivering RNAi platform (sd‑rxRNA).

3 Jun 2015

Medicare physician reimbursement data could be confusing to the public

The Centers for Medicare & Medicaid Services today released to the public data relating to 2013 Medicare payments made to physicians and other providers. In response, the American Academy of Ophthalmology is providing necessary context for the reimbursement data, which in its raw form are often complex and difficult to understand.

2 Jun 2015

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone.

1 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

SNPs predict sunitinib outcome in mRCC

Research has confirmed that single nucleotide polymorphisms in genes related to the processing of sunitinib influence the outcome of treatment for metastatic renal cell carcinoma.

29 May 2015

Patient characteristics may guide TKI use in CML

The likelihood of complications associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia may be reduced by considering patient factors and differences in the toxicity profiles of the different drug options, a review suggests.

29 May 2015

Study could offer new way to treat, prevent diabetes-associated blindness

Reporting on their study with lab-grown human cells, researchers at The Johns Hopkins University and the University of Maryland say that blocking a second blood vessel growth protein, along with one that is already well-known, could offer a new way to treat and prevent a blinding eye disease caused by diabetes.

26 May 2015

Anti-VEGF therapy benefits in wet AMD not sustained

Real-world experience of anti-vascular endothelial growth factor therapy for patients with wet age-related macular degeneration suggests that initial improvements in visual acuity are not maintained over time.

20 May 2015

No added benefit with pazopanib over ranibizumab for neovascular AMD

Pazopanib eye drops do not enhance visual outcomes in patients with neovascular age-related macular degeneration beyond those achieved with ranibizumab alone, study findings indicate.

19 May 2015

Risk factors predict geographic atrophy after anti-VEGF treatment of RAP

Researchers have found three factors that could identify which patients with retinal angiomatous proliferation receiving anti-vascular endothelial growth factor treatment are likely to develop geographic atrophy.

19 May 2015

U.K Ophthalmologists lead in treatment of wet AMD patients with Oraya therapy across europe

Oraya Therapy was introduced first in the U.K., followed by Switzerland and Germany. The therapy is intended as a one-time, non-invasive treatment that maintains vision with fewer anti-vascular endothelial growth factor (anti-VEGF) injections into the eye...

19 May 2015

Trained nurses administer AMD treatments as safely and effectively as doctors

Nurses trained to deliver eye injections for patients with the wet form of age-related macular degeneration (AMD) administered the treatments as safely and effectively as doctors, according to a new study. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Denver, Colo.

6 May 2015